SCHEMBL2361316

SCHEMBL2361316

O=C(O)Cc1c(F)ccc(F)c1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 2/20 0.41
DUSP3 P51452 1/20 0.41
PTPN5 P54829 1/20 0.41
PTPN11 Q06124 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
CXCL8 P10145 2/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
CA2 P00918 1/20 0.34
CAMK2A Q9UQM7 1/20 0.34
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 1/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13244347 0.79 DHODH (0.39) CES2CES1CA2ALDH1A1TDP1
SCHEMBL909585 0.78 AKR1B1 (0.43) AKR1B1CES2CES1CXCL8LMNA
SCHEMBL29459948 0.78 AKR1B1 (0.43) AKR1B1CES2CES1CXCL8LMNA
Hydrochloric Acid SCHEMBL1372127 0.77 AKR1B1 (0.42) AKR1B1CES2CES1CXCL8LMNA
SCHEMBL30048528 0.77 CES2 (0.50) CES2CES1CA2KDM4EALDH1A1
SCHEMBL3309453 0.77 CES2 (0.50) CES2CES1CA2KDM4EALDH1A1
SCHEMBL28397693 0.76 CA1 (0.45) AKR1B1DUSP3PTPN5PTPN11CTDSP1
SCHEMBL1364933 0.76 DUSP3 (0.59) AKR1B1DUSP3PTPN5PTPN11CTDSP1
SCHEMBL503912 0.76 AKR1B1 (0.56) AKR1B1CES2CES1CXCL8POLB
SCHEMBL261516 0.75 AKR1B1 (0.50) AKR1B1CXCL8LMNACA2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2011-09-15 US disclosed
EP-2358682-A2 ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2011-08-24 EP disclosed
WO-2010055164-A2 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION MAVS, IRF3, EIF2AK2 AKR1B1 1119/4885DUSP3 157/4885PTPN5 1969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.